Miglustat

Miglustat
Clinical data
Trade names	Zavesca, Brazaves, Opfolda
Other names	OGT 918, 1,5-(butylimino)-1,5-dideoxy-D-glucitol, N-butyl-deoxynojirimycin (NB-DNJ)
AHFS/Drugs.com	Monograph
MedlinePlus	a604015
License data	EU EMA: by INN; US DailyMed: Miglustat; US FDA: Miglustat;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	A16AX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	97%
Protein binding	Nil
Metabolism	Nil
Elimination half-life	6–7 hours
Excretion	Kidney, unchanged
Identifiers
	IUPAC name (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol;
CAS Number	72599-27-0 ;
PubChem CID	51634;
IUPHAR/BPS	4841;
DrugBank	DB00419 ;
ChemSpider	46764 ;
UNII	ADN3S497AZ;
KEGG	D05032;
ChEBI	CHEBI:50381 ;
ChEMBL	ChEMBL1029 ;
CompTox Dashboard (EPA)	DTXSID6045618 ;
ECHA InfoCard	100.216.074
Chemical and physical data
Formula	C10H21NO4
Molar mass	219.281 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O;
	InChI InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 ; Key:UQRORFVVSGFNRO-UTINFBMNSA-N ;
	(verify)

Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.

It was approved for medical use in the European Union in November 2002, and for medical use in the United States in July 2003.